TL;DR
This study reveals that low levels of the enzyme fumarate hydratase (FH) in colorectal cancer (CRC) patients are linked to a poor prognosis and reduced effectiveness of PD-1 immunotherapy. The researchers found that FH normally inhibits the PCSK9 protein, and when FH is low, PCSK9 increases, suppressing the immune response. Combining PD-1 therapy with a PCSK9 inhibitor shows promise for improving treatment outcomes in CRC patients with low FH expression.
What Problem Does This Paper Address?
Despite the significant advancements in cancer treatment, particularly with immune checkpoint inhibitors like PD-1 antibodies, their efficacy in colorectal cancer (CRC) remains limited for a substantial portion of patients. This lack of response is often attributed to the complex tumor microenvironment (TME) and metabolic reprogramming within tumor cells. Specifically, the study highlights that a downregulation of fumarate hydratase (FH), an enzyme crucial for the tricarboxylic acid (TCA) cycle, is associated with poor prognosis in CRC. The paper aims to elucidate the mechanistic link between FH, tumor metabolism, and the efficacy of PD-1 immunotherapy, seeking to identify strategies to overcome resistance.
Methods
The researchers employed a multi-pronged approach combining bioinformatics analysis, cell-based experiments, and in vivo mouse models.
- Bioinformatics: They utilized datasets from The Cancer Genome Atlas (TCGA) and other public databases (UCSC Xena, GSEA, ChIP-Atlas) to analyze gene expression patterns and identify correlations between FH expression and patient prognosis.
- Cellular Assays: Standard molecular biology techniques were used, including:
- Western Blotting and RT-qPCR: To assess protein and mRNA expression levels of FH, PCSK9, and other key molecules.
- Colony Formation Assay & CCK-8 Assay: To evaluate cell proliferation and colony-forming ability after manipulating FH expression.
- Transwell Assay: To measure cell invasion.
- Immunofluorescence & Co-Immunoprecipitation (Co-IP): To investigate protein localization, interactions, and nuclear translocation.
- RNA-sequencing (RNA-seq): To identify differentially expressed genes in FH-knockdown cells.
- In Vivo Models:
- Mouse Models: They established subcutaneous tumor models in nude mice (for HCT116 cells) and C57BL/6 mice (for MC38 cells) to assess the impact of FH knockdown and therapeutic interventions on tumor growth.
- Therapeutic Interventions: These models were used to test the efficacy of PD-1 antibodies alone, PCSK9 inhibitors alone, and combination therapies.
- Flow Cytometry: To analyze immune cell populations (CD8+ T cells, Tregs) within tumor tissues.
- Immunohistochemistry (IHC): To visualize the expression of key proteins in tumor tissues.
Datasets
The study utilized publicly available datasets for initial analysis:
- The Cancer Genome Atlas (TCGA): For analyzing gene expression and prognosis in colorectal cancer.
- UCSC Xena platform: For data mining.
- Gene Set Enrichment Analysis (GSEA): For pathway analysis.
- ChIP-Atlas: For identifying potential transcription factor binding sites.
Additionally, they collected clinical specimens from 12 CRC patients treated at Union Hospital.
Key Insights and Ideas
- FH as a Prognostic Marker: Low FH expression in CRC is not just a metabolic anomaly but a significant indicator of poor prognosis and reduced sensitivity to PD-1 immunotherapy.
- The FH-PCSK9 Axis: FH acts as a negative regulator of PCSK9. When FH levels are low, PCSK9 expression increases, directly impacting the tumor microenvironment.
- PCSK9's Immunosuppressive Role: Elevated PCSK9 levels, driven by low FH, lead to decreased CD8+ T cell infiltration and activity, thereby dampening the anti-tumor immune response.
- Ran's Crucial Role: The study identified that FH interacts with the protein Ran, which is critical for the nuclear translocation of PCSK9 transcription factors (SREBF1/2). FH's interaction with Ran appears to inhibit this translocation, thereby controlling PCSK9 expression.
- Therapeutic Synergy: Combining PD-1 antibodies with PCSK9 inhibitors shows a significant synergistic effect in enhancing anti-tumor immunity, particularly in models with low FH expression.
Key Results
- FH Downregulation in CRC: FH mRNA and protein levels were significantly lower in CRC tumor tissues compared to adjacent normal tissues.
- FH and Prognosis: Low FH expression was correlated with a poorer prognosis in both colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) cohorts.
- FH Knockdown Promotes Proliferation and Invasion: In CRC cell lines (HCT116 and SW620), knockdown of FH led to increased colony formation and invasion. Conversely, FH overexpression inhibited these processes.
- FH Deficiency Impairs PD-1 Efficacy: In mouse models, knockdown of FH significantly reduced the anti-tumor efficacy of PD-1 antibody monotherapy.
- Mechanism of Action: FH knockdown led to increased nuclear translocation of SREBF1/2, resulting in elevated PCSK9 expression. This, in turn, decreased CD8+ T cell infiltration in tumors.
- Combination Therapy Efficacy: In vivo experiments demonstrated that combining PD-1 antibodies with a PCSK9 inhibitor significantly improved tumor regression in FH-low CRC models.
Limitations and Future Work
The authors acknowledge that the evidence for clinical validation is limited and that further studies with larger cohorts are necessary. They suggest that prospective recruitment research samples should be evaluated to confirm these findings. Future work could also delve deeper into the complex mechanisms of CRC progression and treatment resistance, particularly exploring the detailed interactions of FH and its downstream pathways. The potential of FH as a biomarker and the therapeutic application of PCSK9 inhibitors in combination with PD-1 antibodies for CRC patients with low FH expression warrant further investigation.
Summary updated